Online inquiry

IVTScrip™ mRNA-Anti-TNC, ST2146(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (CAT#: GTTS-WQ15084MR)

This product GTTS-WQ15084MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets TNC gene. The antibody can be applied in Cancers research.

Specifications
Product type	mRNA
Modified bases	5-Methyl-CTP & Pseudo-UTP
5' Cap	Cap 1
Species	Mus musculus
RefSeq	NM_002160.4
Applications	Gene therapy research
Format	Powder
Quantity	100 µg
Purification	oligo-dT affinity purification

Target Gene
Gene ID	3371
UniProt ID	P24821

Download
Download resources about mRNA therapeutics development to boost your research.

CUSTOMER REVIEWS and Q&As
There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNC, ST2146(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ15084MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT	Product Name	Product Type	CDs
GTTS-WQ9457MR	IVTScrip™ mRNA-Anti-KIR3DL2, IPH4102(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))	mRNA	IPH4102
GTTS-WQ237MR	IVTScrip™ mRNA-Anti-B4GALNT1, 14.18 mAb(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))	mRNA	14.18 mAb
GTTS-WQ5596MR	IVTScrip™ mRNA-Anti-IL13, CDP7766(Cap 1, 2-Thio-UTP, 120 nt-poly(A))	mRNA	CDP7766
GTTS-WQ4212MR	IVTScrip™ mRNA-Anti-Factor IX substitute, BIIB029(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))	mRNA	BIIB029
GTTS-WQ9573MR	IVTScrip™ mRNA-Anti-EGFR&MET, JNJ-61186372(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))	mRNA	JNJ-61186372
GTTS-WQ10863MR	IVTScrip™ mRNA-Anti-B4GALNT1, MAb-14.18(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))	mRNA	MAb-14.18
GTTS-WQ12946MR	IVTScrip™ mRNA-Anti-MUC1, PankoMab(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))	mRNA	PankoMab
GTTS-WQ9769MR	IVTScrip™ mRNA-Anti-PDCD1, JS001(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))	mRNA	JS001

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST